Skip to main content
Quest Diagnostics

Paraneoplastic neurological syndromes

Early detection and quick treatment can make a difference

Paraneoplastic neurological syndromes (PNS) are a group of disorders that develop in some people who have cancer. In 60% of patients with PNS, the symptoms occur before the diagnosis of cancer is made.1

Enhanced detection of neuronal cell-surface antigens can accelerate diagnosis and treatment

The Paraneoplastic Antibody Expanded Evaluation from Quest can identify 25 prevalent antibodies, including Ma2/Ta and Zic4. Utilizing CBA methodology as part of the initial panel instead of a reflex increases the likelihood of identifying membrane-embedded protein targets, NMDA (NR1), LGI1, CASPR2, AMPAR, and GABABR.

The Paraneoplastic Antibody Expanded Evaluation from Quest always uses a cell-based assay (CBA) as part of the initial panel assessment 

 

Detection of central nervous system autoantibodies is generally better achieved with CBAs2

 

Utilizing CBA increases the likelihood of identifying membrane-embedded protein targets, LGI1, CASPR2, NMDA (NR1), AMPAR, and GABABR

   3 important reasons to test for PNS
  1. Identify PNS antibodies that can increase the likelihood of early diagnosis and treatment
  2. Understand disease progression and prognosis so you and your patients know what to expect
  3. Discover comorbidities or underlying conditions such as encephalitis, ataxia, or myasthenia gravis so you can plan the right care pathway

By screening patients for multiple autoantibodies, the detection rate for diagnostically relevant autoantibodies increased by 87%, compared to single testing of requested analytes 3

Why order PNS testing from Quest

We use primate tissue for the IFA, which closely mimics human tissue, reducing background noise and improving specificity

A cell-based assay is always run as part of the initial panel, increasing the likelihood of identifying membrane-embedded protein targets NMDA (NR1), LGI1, CASPR2, AMPAR, and GABABR

We include 25 prevalent antibodies, including Ma2/Ta and Zic4 

A complete testing solution to help guide the search for an underlying malignancy

Test name
Paraneoplastic Antibody Expanded Evaluation w/Reflex to Titer and Line Blot, Serum
Paraneoplastic Antibody Expanded Evaluation w/Reflex to Titer and Line Blot, CSF
Paraneoplastic Antibody Evaluation w/Reflex to Titer and Line Blot, Basic, Serum
Paraneoplastic Antibody Evaluation w/Reflex to Titer and Line Blot, Basic, CSF
Autoimmune Neurology Antibody Comprehensive Panel with Reflexes, Serum

References

1. National Organization for Rare Disorders. Paraneoplastic neurologic syndromes. Updated 2016. Accessed October 20, 2021. https://rarediseases.org/rare-diseases/paraneoplasticneurologic-syndromes/

2. Abelhosn RW, Montana L, Rivera JG, et al. Tissue immunofluorescence confirmation of CNS autoantibodies identified by immunoblot or cell-based assay. J Neurosci Neuropsych. 2021;103:4. Online ahead of print, December 15, 2020. http://article.scholarena.com/Tissue-Immunofluorescence-Confirmation-of-CNS.pdf

3. Stocker W, Probst C, Teegen B, et al. Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases. Paper presented at: 2nd International Conference on Antibodies and Therapeutics; July 11-12, 2016; Philadelphia, PA. Immunome Res. 2016;12 (2)(Suppl). https://www.longdom.org/

Join our email community 

Get the very latest news and information from Quest Advanced® Neurology.

Sign up

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.